Clinical Trial Update: Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the immune response and safety of GlaxoSmithKline's HPV vaccine in healthy women aged 18-35; completed with results posted in December …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2009-12-15